(Q34424795)

2 August 2017

title

Initiating dopaminergic treatment in Parkinson's disease (English)

1 reference

Connie Fernández-Cid Marras

2 August 2017

1 reference

1 reference

series ordinal

2

object named as

Connie Marras

1 reference

2 August 2017

1

Anthony E Lang

1 reference

2 August 2017

language of work or name

English

0 references

publication date

11 June 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

384

1 reference

2 August 2017

issue

9949

1 reference

2 August 2017

page(s)

1164-1166

1 reference

"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Pharmacological treatment of Parkinson disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960962-4

7 January 2021

10.1016/S0140-6736(14)60962-4

Identifiers

DOI

1 reference

2 August 2017

1 reference